1000342-11-9

Basic information

• Product Name: Methyl 3-AMino-5-broMo-2-Methylbenzoate
• Synonyms: Methyl 3-AMino-5-broMo-2-Methylbenzoate;Benzoic acid, 3-aMino-5-broMo-2-Methyl-, Methyl ester;Benzoic acid, 3-aMino-5-b...;3-AMino-5-broMo-2-Methyl-benzoicacid Methyl ester;3-amino-5-bromo-2-methylbenzoic acid;EOS-61052
• CAS NO: 1000342-11-9
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• EINECS: -0
• Mol File: 1000342-11-9.mol
• Article Data: 22

Chemical Properties

• Melting Point: 52 °C
• Boiling Point: 336.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.506
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 2.23±0.10(Predicted)
• CAS DataBase Reference: Methyl 3-AMino-5-broMo-2-Methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-AMino-5-broMo-2-Methylbenzoate(1000342-11-9)
• EPA Substance Registry System: Methyl 3-AMino-5-broMo-2-Methylbenzoate(1000342-11-9)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 1000342-11-9(Hazardous Substances Data)

Usage

General Description

Methyl 3-amino-5-bromo-2-methylbenzoate is a chemical compound with the molecular formula C10H11BrNO2. It is a derivative of benzoic acid and contains a bromine atom, a methyl group, and an amino group attached to the benzene ring. Methyl 3-amino-5-bromo-2-methylbenzoate is commonly used in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and active pharmaceutical ingredients due to its unique chemical structure and properties. Methyl 3-amino-5-bromo-2-methylbenzoate may also be used as an intermediate in the production of other organic compounds and materials.

InChI:InChI=1S/C9H10BrNO2/c1-5-7(9(12)13-2)3-6(10)4-8(5)11/h3-4H,11H2,1-2H3

Upstream product

• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 220514-28-3 5-bromo-2-methyl-3-nitrobenzoic acid methyl ester 
• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 

Downstream Products

• 1403257-14-6 methyl 5-bromo-3-(cyclopentyl(methyl)amino)-2-methylbenzoate 
• 1403257-15-7 5-bromo-3-(cyclopentyl(methyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methylbenzamide 
• 1403257-17-9 5-(cyclopentyl(methyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-formyl-4-methyl-[1,1'-biphenyl]-3-carboxamide 
• 1403254-55-6 EPZ₀₀₆₀₈₈ 
• 1403254-56-7 5-(cyclopentylamino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((dimethylamino)methyl)-4-methyl-[1,1'-biphenyl]-3-carboxamide 
• 1403257-18-0 5-bromo-3-(cyclopentylamino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methylbenzamide 
• 1403256-15-4 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl-d₅(tetrahydro-2H-pyran-4-yl)amino)-4'-formyl-4-methyl-[1,1'-biphenyl]-3-carboxamide 
• 1403258-61-6 5-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl-d₅ (tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide 
• 1403258-59-2 C₁₆H₂₂BrNO₄ 
• 1403256-09-6 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-thiopyran-4-yl)amino)-4,4'-dimethyl-[1,1'-biphenyl]-3-carboxamide 
• 1403258-42-3 C₁₅H₂₀BrNO₂S 
• 1403258-30-9 tert-butyl ((1R,4R)-4-((5-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)-methyl)-carbamoyl)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-(ethyl)-amino)-cyclohexyl)-carbamate 
• 1403258-29-6 tert-butyl ((1R,4R)-4-((5-bromo-3-(((4,6-dimethyl-2-oxo-1,2-dihydro-3-yl)methyl)carbamoyl)-2-methylphenyl)(ethyl)amino)cyclohexyl)carbamate 
• 1403258-25-2 C₂₀H₂₉BrN₂O₄ 

Relevant articles and documents

The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor

By targeting the unique Cys663 of EZH2, SKLB-0335 displays high paralog-selectivity on EZH2. Biochemical studies show that SKLB-0335 can covalently bind to EZH2 at its S-adenosylmethionine (SAM) pocket and inhibit H3K27Me3. SKLB-0335 could be an effective chemical probe with which to further investigate the specific biological functions of EZH2.

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2

EZH2 mediates both PRC2-dependent gene silencing via catalyzing H3K27me3 and PRC2-independent transcriptional activation in various cancers. Given its oncogenic role in cancers, EZH2 has constituted a compelling target for anticancer therapy. However, current EZH2 inhibitors only target its methyltransferase activity to downregulate H3K27me3 levels and show limited efficacy because of inadequate suppression of the EZH2 oncogenic activity. Therefore, therapeutic strategies to completely block the oncogenic activity of EZH2 are urgently needed. Herein, we report a series of EZH2-targeted proteolysis targeting chimeras (PROTACs) that induce proteasomal degradation of PRC2 components, including EZH2, EED, SUZ12, and RbAp48. Preliminary assessment identified E7 as the most active PROTAC molecule, which decreased PRC2 subunits and H3K27me2/3 levels in various cancer cells. Furthermore, E7 strongly inhibited transcriptional silencing mediated by EZH2 dependent on PRC2 and transcriptional activation mediated by EZH2 independent of PRC2, showing significant antiproliferative activities against cancer cell lines dependent on the enzymatic and nonenzymatic activities of EZH2.